Loading
Histone Deacetylase Inhibitors Research / Cancer, Hypoxia, and Metabolism / Angiogenesis and VEGF in Cancer · Journal article
Journal of Computational Biophysics and Chemistry · August 7, 2026
Raises a question worth testing. It does not answer one.
This is a rational drug design study that uses computational chemistry and cell-based assays to characterize a novel benzanilide derivative (ACEB-Cl) as a potential VEGFR-2 inhibitor. The compound shows favorable binding predictions, potent enzyme inhibition in vitro, and induction of cell-cycle arrest and apoptosis in cancer cells, but lacks in vivo efficacy or safety data required to assess therapeutic potential.
In silico molecular modeling and in vitro biochemical screening. In vitro model: MDA-MB-231 human breast cancer cells and Vero normal mammalian cells. No human subjects or intact organisms studied.. Intervention: ACEB-Cl, a novel benzanilide-based VEGFR-2 inhibitor.. Compared with: Sorafenib (mentioned qualitatively as a reference compound; no formal comparative assay data provided)..
Computational modeling predicted stable ACEB-Cl binding with favorable binding free energy (ΔG = −63.21 kcal/mol) ELISA-based VEGFR-2 inhibition assay showed IC50 = 0.086 ± 0.002 μM, reportedly higher potency than sorafenib Western blot confirmed downregulation of phosphorylated VEGFR-2 in MDA-MB-231 breast cancer cells
ADMET and toxicity data appear to be computational predictions only; no experimental pharmacokinetic or in vivo safety studies presented. In vitro cytotoxicity studies demonstrated selective anticancer activity with reduced toxicity to normal Vero cells
This finding does not yet inform clinical practice. ACEB-Cl is a computational and in vitro lead that requires in vivo efficacy and toxicology studies, as well as pharmacokinetic validation in animal models, before any clinical evaluation could be considered.
This is early-stage drug discovery work using computational and in vitro methods to identify a lead compound; it lacks any in vivo efficacy data, clinical outcomes, or human studies needed to support therapeutic claims.
As stated by the source record.
Quoted from the source exactly as published.
This finding does not yet inform clinical practice. ACEB-Cl is a computational and in vitro lead that requires in vivo efficacy and toxicology studies, as well as pharmacokinetic validation in animal models, before any clinical evaluation could be considered.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
The development of selective vascular endothelial growth factor receptor-2 (VEGFR-2) inhibitors remains a promising strategy for anticancer therapy targeting tumor angiogenesis. In the study at hand, a novel benzanilide-based derivative, ACEB-Cl, was rationally designed by assimilating fundamental pharmacophoric characteristics essential for VEGFR-2 inhibition. ACEB-Cl was evaluated using a comprehensive approach that combined computational modeling, synthesis, and in vitro biological assessment. Density functional theory (DFT) calculations revealed a favorable electronic profile, with distinct nucleophilic and electrophilic regions that could support potential interactions within the VEGFR-2 binding pocket. Docking and molecular dynamics (MD) simulations suggested stable binding of ACEB-Cl within the ATP-binding pocket, supported by strong hydrophobic interactions and favorable binding free energy (ΔG = −63.21 kcal/mol). Following synthesis, ACEB-Cl confirmed potent anti-VEGFR-2 activity in an ELISA-based assay (IC50 = 0.086 0.002 M), showing higher potency than sorafenib. Western blot analysis further confirmed significant downregulation of phosphorylated VEGFR-2 in MDA-MB-231 cells. In vitro cytotoxicity studies revealed selective anticancer activity, with reduced toxicity toward normal Vero cells and favorable selectivity indices. Mechanistically, ACEB-Cl triggered G0/G1 phase arrest and significantly increased apoptotic cell death, highlighting its ability to suppress cancer cell proliferation. Additionally, ADMET and toxicity estimations indicated a balanced pharmacokinetic and safety profile, with improved solubility, acceptable absorption, and reduced toxicity risks compared to sorafenib. Overall, this integrated study pinpointed ACEB-Cl as a promising VEGFR-2targeted anticancer lead compound with strong inhibitory potency, and a clearly defined mechanism of action, supporting its progression for further improvement.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.